Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov:90:13-29.
doi: 10.1016/j.steroids.2014.06.012. Epub 2014 Jun 24.

Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential

Ilaria Paterni  1 , Carlotta Granchi  1 , John A Katzenellenbogen  2 , Filippo Minutolo  3
Affiliations
Review

Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential

Ilaria Paterni et al. Steroids. 2014 Nov.

Abstract

Estrogen receptors alpha (ERα) and beta (ERβ) are nuclear transcription factors that are involved in the regulation of many complex physiological processes in humans. Modulation of these receptors by prospective therapeutic agents is currently being considered for prevention and treatment of a wide variety of pathological conditions, such as, cancer, metabolic and cardiovascular diseases, neurodegeneration, inflammation, and osteoporosis. This review provides an overview and update of compounds that have been recently reported as modulators of ERs, with a particular focus on their potential clinical applications.

Keywords: Agonists; Antagonists; Estrogen receptor subtype α; Estrogen receptor subtype β; Modulators; Therapeutic applications.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Steroids derivatives.
Fig. 2
Fig. 2
Benzopyran derivatives 16–22.
Fig. 3
Fig. 3
Cyclohexylphenol 23, cyclopentylene 24, and diphenylmethane derivative 25.
Fig. 4
Fig. 4
Structure of ERB-041 26, KB9520 27 and chloroindazole 28.
Fig. 5
Fig. 5
Separate enantiomers of DPN.
Fig. 6
Fig. 6
Tetrahydrofluorenone derivatives.
Fig. 7
Fig. 7
β-LGND1 and β-LNGD2 compounds.
Fig. 8
Fig. 8
Schiff base derivatives: oximes (36–39) and imines (40–41).
Fig. 9
Fig. 9
Carborane derivatives.
Fig. 10
Fig. 10
Phytoestrogen compounds 44–53.
Fig. 11
Fig. 11
ERβ selective ligands useful for PET studies.
See this image and copyright information in PMC

References

    1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM. Writing Group for the Women’s Health Initiative: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. - PubMed
    1. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JÅ International Union of Pharmacology. LXIV. Estrogen Receptors. Pharmacol Rev. 2006;58:773–781. - PubMed
    1. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, Gustafsson JÅ. Estrogen receptors: how do they signal and what are their targets. Physiological Reviews. 2007;87:905–931. - PubMed
    1. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res. 2001;61:5683–5687. - PubMed
    1. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, Öhman L, Greene GL, Gustafsson JÅ, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753–758. - PubMed

Publication types

MeSH terms